GreenLight SPAC Presentation Deck

Human Health pipeline focused on large and significant markets mRNA design flexibility coupled with our production capability can enable rapid development of vaccines and therapies Application -CEH HED -CEH Vaccine Vaccine Gene Therapy Target Vaccine COVID-19 updated for VoC Seasonal influenza Sickle Cell Disease gene Antibody Antibody Therapy undisclosed Supra-seasonal influenza Collaborator ACADEMIC PARTNER ACADEMIC PARTNER BILL & MELINDA GATES foundation Funder ACADEMIC PARTNER ACADEMIC PARTNER Early Pre- clinical Pre-clinical Toxicity Pre-IND submitted to FDA* 11 * Clinical Development Phase 1 | Phase 2 | Phase 3 Investor Presentation | © 2021 GreenLight Biosciences. All rights reserved. GreenLight confidential. M M M M Anticipated Clinical Development Start Date H1 2022 H2 2022 TBD TBD H1 2024 Target timing to seek development/commercialization partnership Candidate selected and toxicology studies to be initiated HUMAN HEALTH 23

View entire presentation